Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enteric-coated mycophenolate sodium for GI intolerance in renal transplant patients
NCT00150020Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in gastrointestinal intolerance, sponsored by Novartis. Primary endpoint: Gastrointestinal Symptom Rating Scale at 3 months. Started Oct 2004; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
gastrointestinal intolerance
Beyond the preview
Go deeper on NCT00150020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150020.